Business
Jul 22, 2026
As AstraZeneca exited the first quarter, initially skeptical analysts were coming around to the potential for the drugmaker to hit its goal of growing sales to $80…
Jul 22, 2026
Royalty Pharma has secured a stake in another transthyretin-mediated (ATTR) amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the…
Jul 19, 2026
ROLE SUMMARYThe Medical Engagement, Strategy & Insights Director provides senior scientific and medical expertise in Transthyretin Amyloid Cardiomyopathy (ATTR-…
Jul 14, 2026
What's going on here?BofA Securities just got more cautious on Alnylam’s heart-drug story, trimming its peak sales view to $11.8 billion and cutting its price…
Jul 13, 2026
The global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market was valued at USD 5.85 billion in 2025 and is projected to reach USD 64.09 billion by 2033, growing…
Jul 07, 2026
Austin, United States, July 07, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Transthyretin Amyloidosis Treatment Market was valued at USD 8.95 Billion in…
Jul 07, 2026
Job Position PurposeAct as the Amyloidosis team lead and line manager, leading a team of MAS. Shape the local strategy and ensure the delivery of scientific-medical…
Jul 03, 2026
The Transthyretin Amyloidosis Treatment Market is Segmented by Therapy (Targeted Therapy, Supportive Therapy, Pipeline Therapy), Type (ATTR with Polyneuropathy (…
Jul 01, 2026
“AL Amyloidosis Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects…
Jun 12, 2026
Alnylam Pharmaceuticals ALNY is a commercial-stage company that currently markets four drugs. The company first received regulatory approval in 2018 for…